🇺🇸 FDA
Patent

US 10676528

Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same

granted A61PA61P35/00A61P35/02

Quick answer

US patent 10676528 (Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P35/00, A61P35/02